Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLIMMER-UP-SWITCH: Phase 2 randomized open-label study of XW003 versus semaglutide in adults with obesity
CTR20252734Phase 2Active
- Sponsor
- Sciwind Biosciences
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of ecnoglutide, semaglutide in obesity, Overweight, sponsored by Sciwind Biosciences. Started Jul 2025; status: active.
02
Drugs
ecnoglutidesemaglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20252734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252734.